ophthalmology

News

After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.

News

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved therapy for idiopathic macular telangiectasia type 2.

News

Astellas has shored up the competitive profile of Izervay for eye disorder geographic atrophy, getting FDA approval for extended treatment.

News

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.

News

A UK alliance between data scientists, clinical researchers, and community opticians hopes to develop an AI to predict dementia during an eye test.

News

Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.